Loading the company…
Loading the company…
In the last ten years FDA made 2 decisions for Abk Biomedical (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2024 (1). The latest was on 2024-02-13.
| Family | Decisions on record |
|---|---|
| Tumor & fibroid embolization | 2 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2024-02-13 | 510(k) | K234123 | Easi-Vue® embolic microspheres System |
| 2022-09-07 | 510(k) | K220567 | Easi-Vue embolic microspheres System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Abk Biomedical.
In 2025, Abk Biomedical reported engagement with 46 surgeons and other clinicians in the states MedaRep covers, worth $267K in consulting, speaking, meals and travel for its device products, the most in New York ($121K to 4). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($121K, 4 engaged), Illinois ($31K, 6 engaged), North Carolina ($31K, 2 engaged), Georgia ($26K, 2 engaged), Massachusetts ($19K, 2 engaged).